Immunotherapy vs Targeted TherapyVideo Categories: 2018 AONN Midyear, Immunotherapy, and Video Library
Dr Morganna Freeman explains the difference between immunotherapies and targeted therapies in plain language for patients to easily understand.
Dr. S. Yosuf Zafar talks about understanding and considering value from a societal perspective as well as value from the patient’s perspective when making decisions about cost-effectiveness.
Ixazomib may have the potential for great combinability with other drugs, according to Dixie-Lee Esseltine, MD and George Mulligan, PhD. Combination therapy improves compliance, adherence, and quality of life among patients.